

PRESS RELEASE

UK launches FibCLOT[®] [▼], LFB's human fibrinogen concentrate

London, 1st March 2017 – LFB Biopharmaceuticals announced today the UK launch of FibCLOT, its human fibrinogen concentrate. This follows the granting of a UK Marketing Authorisation in April 2016, following a decentralised application to the Regulatory Authorities in Europe, and offers increased therapeutic choices for affected patients.

FibCLOT[®] is indicated for the treatment and perioperative prophylaxis of bleeding in patients with congenital hypo- or afibrinogenaemia with a tendency to bleed¹. These are rare bleeding disorders affecting approximately one in a million people². A clinical study in children¹ has also recently been completed, with the largest cohort of paediatric patients ever included in such a trial to date.

The LFB Group is currently increasing its production capacity to make this cutting-edge treatment even more accessible. New industrial units in Lille and a new plant in Arras, both in northern France, will allow LFB to manufacture up to 300 kg of fibrinogen for supply to healthcare professionals within the next ten years.

About congenital fibrinogen deficiency: Congenital fibrinogen deficiency is a rare, potentially life-threatening genetic bleeding disorder affecting approximately one in a million people. As fibrinogen, also known as Factor I (one), is necessary for blood clot formation, reduced, absent or abnormal amounts of fibrinogen affect the body's ability to form a clot effectively. Symptoms of congenital fibrinogen deficiency include excessive bleeding following an injury, surgery or childbirth, nosebleeds, mouth bleeds, easy bruising, bleeding of the umbilical cord at birth, spontaneous bleeding, joint or mouth bleeds and problems during pregnancy.

In the UK, support for patients is available through the Haemophilia Society (www.haemophiliasociety.org.uk).

About LFB Biopharmaceuticals Ltd: LFB Biopharmaceuticals Ltd (www.lfbbiopharmaceuticals.co.uk) is LFB's second active promotional subsidiary in Europe, following the successful establishment of LFB GmbH in Germany. In France, LFB is a major biopharmaceutical player, leading the French plasma derivatives market, and a top supplier of hospital medicines in the country.

About LFB:

The LFB group (www.lfb-group.com) is a biopharmaceutical company that develops, manufactures, and markets medicinal products for the treatment of serious and often rare diseases in the fields of immunology, haemostasis, perinatal and intensive care. The LFB group is the leading manufacturer of plasma-derived medicinal products in France and 6th worldwide, and is also among the leading European companies for the development of new-generation medicinal products or treatments based on biotechnologies.

The LFB group is pursuing a growth strategy that seeks to extend its international activities and develop innovative therapies. Today, the LFB group currently markets its products in more than 40

countries around the world with a global turnover of €502 million in 2015, 30% of which is generated by international business.

References

1. FibCLOT® Summary of Product Characteristics
2. http://www.orpha.net/consor/cgi-bin/OC_Exp.php?Expert=335 accessed 15th February 2017

PRESS CONTACT

Jane SHEPARD

Tel : +44 7767 755396

email : shepardj@lfb-group.com